Table 1 Case series and studies of biologics in enteropathic arthritis
From: Etanercept in the treatment of recalcitrant enteropathic arthritis: a case report
Study | Number of patients | Study protocol | Outcome |
|---|---|---|---|
Ellman et al. [17] Open-label | four (treatment refractory peripheral arthritis) | Infliximab 5 mg/kg | 100% improvement of arthritis |
Van den Bosch et al. [13] | four CD | Infliximab | 100% improvement in axial and peripheral arthritis |
Herfarth et al. [18] Open-label | 59 (peripheral arthritis refractory to corticosteroids, 6-mercaptopurine, azathioprine, or methotrexate) | Infliximab 5 mg/kg at 0 (luminal CD) or 0, two, and six weeks (fistulizing CD) | 61% (35/59) improvement of 1 point in the arthritis component of the Crohn disease activity index (CDAI) score at 12 weeks and complete resolution of arthritis in 27/59 patients (46%) |
Kaufman et al. [19] Open-label | 22 CD one ulcerative colitis 11 inflammatory arthralgias (three active synovitis) 11 axial/sacroilitis | Infliximab 5 mg/kg | After two weeks, partial improvement in duration of morning stiffness, tender joint count, and visual analogue scale for pain in 7/11 patients. Clear improvement in frank arthritis in one out of three patients |
Van den Bosch et al. [20] Randomized, double-blind, placebo-controlled trial | 40 (SpA with or without inflammatory bowel disease) versus placebo | Infliximab 5 mg/kg at 0, two, and six weeks or placebo | At 12 weeks, improvement in patient and physician global assessment (18 in infliximab group versus 69 in placebo group, P < 0.001) and physician global assessment (16.5 versus 72, P < 0.001). |
Generini et al. [21] Randomized controlled study | 24 CD with SpA (16 active CD and eight inactive CD) versus 12 control subjects (active CD treated with corticosteroids, azathioprine, salicylates, and antibiotics) | Infliximab 5 mg/kg at 0, two, and six weeks followed by 3 mg/kg (inactive CD) or 5 mg/kg (active CD) every five to eight weeks | Improvement of enthesitis or BASDAI or both at six, 12, and 18 months in all patients |
Marzo-Ortega et al. [14] | 10 (7 ankylosing spondylitis, two CD, and one undifferentiated SpA) | Subcutaneous etanercept 25 mg biweekly for 24 weeks | All patients achieving greater than 50% improvement of BASDAI at four weeks and throughout study period |